- Home
- MIN vs ALDX Comparison
MIN vs ALDX Comparison
Compare MIN & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIN
- ALDX
- Stock Information
- Founded
- MIN 1988
- ALDX 2004
- Country
- MIN United States
- ALDX United States
- Employees
- MIN N/A
- ALDX N/A
- Industry
- MIN Trusts Except Educational Religious and Charitable
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- MIN Finance
- ALDX Health Care
- Exchange
- MIN Nasdaq
- ALDX Nasdaq
- Market Cap
- MIN 302.7M
- ALDX 296.0M
- IPO Year
- MIN N/A
- ALDX 2014
- Fundamental
- Price
- MIN $2.66
- ALDX $5.17
- Analyst Decision
- MIN
- ALDX Strong Buy
- Analyst Count
- MIN 0
- ALDX 2
- Target Price
- MIN N/A
- ALDX $9.50
- AVG Volume (30 Days)
- MIN 331.0K
- ALDX 670.9K
- Earning Date
- MIN 01-01-0001
- ALDX 11-05-2025
- Dividend Yield
- MIN 7.31%
- ALDX N/A
- EPS Growth
- MIN N/A
- ALDX N/A
- EPS
- MIN 0.08
- ALDX N/A
- Revenue
- MIN N/A
- ALDX N/A
- Revenue This Year
- MIN N/A
- ALDX N/A
- Revenue Next Year
- MIN N/A
- ALDX $63.48
- P/E Ratio
- MIN $33.38
- ALDX N/A
- Revenue Growth
- MIN N/A
- ALDX N/A
- 52 Week Low
- MIN $2.52
- ALDX $1.14
- 52 Week High
- MIN $2.88
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- MIN 57.42
- ALDX 53.01
- Support Level
- MIN $2.63
- ALDX $4.70
- Resistance Level
- MIN $2.64
- ALDX $5.35
- Average True Range (ATR)
- MIN 0.03
- ALDX 0.26
- MACD
- MIN 0.01
- ALDX 0.01
- Stochastic Oscillator
- MIN 77.71
- ALDX 79.22
About MIN MFS Intermediate Income Trust
MFS Intermediate Income Trust is a diversified closed-end management investment company. The fund's investment objective is to seek high current income but may also consider capital appreciation. It invests the assets in debt instruments. Its portfolio of investments comprises of different sector investments such as the automotive, chemicals, energy, food and beverages, insurance, and other sectors.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.